TAFRO syndrome was effectively treated with an inexpensive novel scheme: A case report

Shan Meng; Hailing Liu; Wanggang Zhang; Aili He; Honghong Sun; Ru Zhang; Xiaoli Chen; Yinxia Chen

doi:10.1002/ccr3.6183

TAFRO syndrome was effectively treated with an inexpensive novel scheme: A case report

Clin Case Rep. 2023 Feb 10;11(2):e6183. doi: 10.1002/ccr3.6183. eCollection 2023 Feb.

Authors

Shan Meng¹, Hailing Liu¹, Wanggang Zhang¹, Aili He¹, Honghong Sun², Ru Zhang³, Xiaoli Chen⁴, Yinxia Chen¹

Affiliations

¹ Department of Hematology The Second Affiliated Hospital of Xi'an Jiaotong University Xi'an China.
² Medical Imaging Department The Second Affiliated Hospital of Xi'an Jiaotong University Xi'an China.
³ Department of Neurology The Second Affiliated Hospital of Xi'an Jiaotong University Xi'an China.
⁴ Pathology Department The Second Affiliated Hospital of Xi'an Jiaotong University Xi'an China.

Abstract

A man diagnosed as TAFRO syndrome was successfully responded to a novel immunosuppressive regimen containing methylprednisolone and mycophenolate mofetil. Blood cells firstly recovered, followed by the general situation and complete recover 1 month later, highlighting the danger of TAFRO syndrome and the importance of immunosuppressive agents in reversing pathological course.

Keywords: Castleman disease; hematology; immunosuppressive agents; oncology.

Publication types

Case Reports